Login to Your Account



Biotie Therapies Walks Away From Newron Acquisition

By Cormac Sheridan
BioWorld Today Correspondent

Monday, October 31, 2011

Biotie Therapies Oyj has closed the door on its proposed stock-based acquisition of Newron Pharmaceuticals SpA, following Merck Serono SA's surprise decision to exit a partnership with Newron on the Parkinson's drug safinamide.

Merck Serono, a division of Darmstadt, Germany-based Merck KGaA dropped a bomb on the acquisition process last week by indicating it would hand back rights to Safinamide, which is undergoing separate Phase III trials as an adjunct to dopamine agonist therapy in early stage Parkinson's and as an adjunct to levodopa therapy in mid-to-late-stage Parkinson's, nex

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription